Colorectal Cancer Stage IV Clinical Trial
Official title:
Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
This study investigates the predictive and prognostic values of inflammatory markers and microRNA in stage IV colorectal cancer. The expression of inflammatory markers and microRNA in plasma will be correlated with tumor location, with dietary patterns and with survival during treatment.
Colorectal cancer (CRC) is responsible for 10% of the world-wide cancer incidence and mortality. Recent data have shown that tumors arising from different regions of the colon differ in their molecular characteristics which causes translate into a differential clinical outcome.Several studies described the role of microRNA expression in the initiation and progression of CRC and its response to different therapeutic strategies. Other studies have shown that systemic inflammation is a key determinant role of clinico-pathological outcomes in patients with CRC. We therefore aim to evaluate the expression of selected microRNA and inflammatory markers in patients with stage IV colorectal cancer and assess their correlation with tumor location, dietary patterns, survival rates, response to systemic chemotherapy and other clinic-pathological parameters. We believe that identifying a predictive and prognostic panel made up of circulating microRNA and inflammatory markers may perhaps explain the difference in outcome between right and left colon and perhaps impact the clinical practice in patients with stage IV colorectal cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03594448 -
Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
|
||
| Active, not recruiting |
NCT03986541 -
AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
|
||
| Completed |
NCT01570452 -
Matrilysin Expression in Different Stages of Colorectal Tumors
|
N/A | |
| Recruiting |
NCT05354817 -
Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin
|
Phase 2 | |
| Recruiting |
NCT05576896 -
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
|
Phase 2 | |
| Completed |
NCT04715061 -
Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments
|
N/A | |
| Terminated |
NCT03149679 -
The p53 Colorectal Cancer Trial
|
Phase 2 | |
| Completed |
NCT05550701 -
Prognostic Impact of Increased Lymph Node Yield in Colorectal Cancer Patients With Synchronous Distant Metastasis: a Population-based Study of the US Database and a Chinese Registry
|
||
| Completed |
NCT04425239 -
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT06329700 -
Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
|
||
| Recruiting |
NCT05382741 -
Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
|
Phase 2 | |
| Recruiting |
NCT06342440 -
Early Detection of Advanced Adenomas and Colorectal Cancer
|
||
| Not yet recruiting |
NCT04917276 -
Treatment Response Prediction System of mCRC Patients Based on CTC
|
||
| Not yet recruiting |
NCT06296056 -
Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care
|
Phase 1 | |
| Recruiting |
NCT04714814 -
Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
|
||
| Not yet recruiting |
NCT05451719 -
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
|
Phase 2 | |
| Completed |
NCT03031444 -
Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis
|
Phase 2/Phase 3 | |
| Completed |
NCT05164419 -
Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
|
||
| Recruiting |
NCT05171660 -
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
|
Phase 3 | |
| Recruiting |
NCT05426005 -
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
|
Phase 1/Phase 2 |